Sign in

Tom Costas

Research Analyst at Private Investor

No publicly available information could be verified regarding Tom Costas as an analyst at Private Investor, including details about exact job title, coverage universe, performance metrics, career timeline, or professional credentials. There are no confirmed LinkedIn profiles or analyst platform results matching these search criteria, and no quantitative performance data or relevant achievements could be found. Without validated professional records or credentials, a comprehensive professional profile cannot be established at this time.

Tom Costas's questions to XBiotech (XBIT) leadership

Question · Q2 2016

Tom Costas, a private investor, asked about a critical review from an individual at the European Society of Medical Oncology (ESMO) regarding the company's Phase 3 study and questioned its potential impact on the European medical community's adoption of Xilonix upon approval.

Answer

Founder, President & CEO John Simard dismissed the review as not credible, highlighting the reviewer's undisclosed affiliation as a spokesperson for Regorafenib, a competitor drug. Simard stated that the company saw no new insights in the analysis and could not speculate on how one individual's opinion might influence the broader medical community.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts